GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advaxis Inc (OTCPK:ADXS) » Definitions » Cyclically Adjusted PB Ratio

Advaxis (Advaxis) Cyclically Adjusted PB Ratio : 0.00 (As of May. 02, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Advaxis Cyclically Adjusted PB Ratio?

As of today (2024-05-02), Advaxis's current share price is $0.6431. Advaxis's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2023 was $1,366.28. Advaxis's Cyclically Adjusted PB Ratio for today is 0.00.

The historical rank and industry rank for Advaxis's Cyclically Adjusted PB Ratio or its related term are showing as below:

ADXS's Cyclically Adjusted PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.74
* Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Advaxis's adjusted book value per share data for the three months ended in Mar. 2023 was $2.027. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $1,366.28 for the trailing ten years ended in Mar. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Advaxis Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Advaxis's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advaxis Cyclically Adjusted PB Ratio Chart

Advaxis Annual Data
Trend Oct13 Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.06 -

Advaxis Quarterly Data
Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Mar23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 - - -

Competitive Comparison of Advaxis's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Advaxis's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advaxis's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Advaxis's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Advaxis's Cyclically Adjusted PB Ratio falls into.



Advaxis Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Advaxis's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.6431/1366.28
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advaxis's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2023 is calculated as:

For example, Advaxis's adjusted Book Value per Share data for the three months ended in Mar. 2023 was:

Adj_Book=Book Value per Share/CPI of Mar. 2023 (Change)*Current CPI (Mar. 2023)
=2.027/127.3478*127.3478
=2.027

Current CPI (Mar. 2023) = 127.3478.

Advaxis Quarterly Data

Book Value per Share CPI Adj_Book
201304 -1,647.382 98.107 -2,138.378
201307 -1,648.775 98.557 -2,130.429
201310 1,574.978 98.536 2,035.510
201401 1,273.350 98.692 1,643.080
201404 1,727.387 100.023 2,199.279
201407 1,431.304 100.520 1,813.301
201410 1,261.002 100.176 1,603.045
201501 1,568.432 98.604 2,025.652
201504 2,066.798 99.824 2,636.673
201507 3,715.619 100.691 4,699.301
201510 4,131.487 100.346 5,243.195
201601 3,719.236 99.957 4,738.384
201604 3,333.088 100.947 4,204.803
201607 2,908.838 101.524 3,648.752
201610 3,575.127 101.988 4,464.099
201701 3,206.002 102.456 3,984.888
201704 2,729.620 103.167 3,369.392
201707 2,176.786 103.278 2,684.109
201710 1,580.082 104.070 1,933.510
201801 1,114.387 104.578 1,357.027
201804 1,037.785 105.708 1,250.233
201807 757.523 106.324 907.311
201810 414.959 106.695 495.282
201901 645.328 106.200 773.833
201904 430.623 107.818 508.623
201907 204.767 108.250 240.893
201910 62.996 108.577 73.887
202001 55.180 108.841 64.563
202004 47.051 108.173 55.391
202007 40.138 109.318 46.758
202010 30.925 109.861 35.848
202101 25.885 110.364 29.868
202104 26.120 112.673 29.522
202107 24.322 115.183 26.891
202110 21.361 116.696 23.311
202201 21.175 118.619 22.733
202204 19.309 121.978 20.159
202207 15.526 125.002 15.817
202210 13.011 125.734 13.178
202303 2.027 127.348 2.027

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Advaxis  (OTCPK:ADXS) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Advaxis Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Advaxis's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Advaxis (Advaxis) Business Description

Industry
Traded in Other Exchanges
N/A
Address
9 Deer Park Drive, Suite K-1, Monmouth Junction, NJ, USA, 8540
Advaxis Inc is a clinical-stage biotechnology company operating in the United States. It focuses on the discovery, development, and commercialization of proprietary Lm (Listeria monocytogenes)-LLO (Listeriolysin O) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. The company's immunotherapy products based on Lm-LLO immunotherapy are Axalimogene filolisbac (AXAL) which targets Human Papilloma Virus (HPV) - associated cancers and ADXS-PSA which targets Prostate-Specific Antigen (PSA) associated with prostate cancer.
Executives
Roy Golan officer: Chief Financial Officer 24 GOLDA MEIR ST., HOLON L3 5840425
Yuval Cabilly director C/O BIOSIGHT THERAPEUTICS, 4 HASADOT STREET, RAMAT HASHARON L3 4704348
Pini Orbach director C/O BIOSIGHT THERAPEUTICS, 3 HAYARDEN STREET, AIRPORT CITY L3 7019802
Bridget A Martell director C/O POINT BIOPHARMA GLOBAL INC., 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Israel Biotech Fund Ii, L.p. 10 percent owner 4 OPPENHEIMER ST., REHOVOT L3 7670104
Israel Biotech Fund Gp Partners Ii, L.p. 10 percent owner 4 OPPENHEIMER ST., REHOVOT L3 7670104
Murray A Goldberg director 2030 MAIN STREET, SUITE 1500, IRVINE CA 92614
Robert J. Spiegel director C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Vered Bisker-leib director C/O COMPASS, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142
Israel Biotech Fund I, L.p. 10 percent owner 4 OPPENHEIMER ST., REHOVOT L3 7670104
Amoon Growth Fund Limited Partnership 10 percent owner 34 YERUSHALAYIM RD., RAANANA L3 4350110
Israel Biotech Fund Gp Partners, L.p. 10 percent owner 4 OPPENHEIMER ST., REHOVOT L3 7670104
Yair Chaim Schindel 10 percent owner YERUSHALAYIM ROAD 34, BEIT GAMLA ENTRANCE B, RA'ANANA L3 4350110
I.b.f. Management Ltd. 10 percent owner 4 OPPENHEIMER ST., REHOVOT L3 7670104
Igor Gitelman officer: Chief Accounting Officer 201 ROUTE 17 N., 2ND FLOOR, RUTHERFORD NJ 07070

Advaxis (Advaxis) Headlines

From GuruFocus

Advaxis, Inc. Announces 1-for-80 Reverse Stock Split

By GuruFocusNews GuruFocusNews 07-07-2022